Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia

Patients with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) and patients whose minimal residual disease persists during treatment have a poor leukemia-free survival. Despite improvements in front-line therapy, the outcome in these patients remains poor, especially after re...

Full description

Bibliographic Details
Main Authors:	Le Jeune, Caroline, Thomas, Xavier
Format:	Online
Language:	English
Published:	Dove Medical Press 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762579/

id	pubmed-4762579
recordtype	oai_dc
spelling	pubmed-47625792016-03-02 Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia Le Jeune, Caroline Thomas, Xavier Review Patients with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) and patients whose minimal residual disease persists during treatment have a poor leukemia-free survival. Despite improvements in front-line therapy, the outcome in these patients remains poor, especially after relapse. As there are no standard chemotherapeutic regimens for the treatment of patients with R/R B-precursor ALL, T-cell-based therapeutic approaches have recently come to the forefront in ALL therapy. Recently, monoclonal antibodies have been developed to target specific antigens expressed in B-lineage blast cells. In this setting, CD19 is of great interest as this antigen is expressed in B-lineage cells. Therefore, it has been selected as the target antigen for blinatumomab, a new bi-specific T-cell engager antibody. This sophisticated antibody binds sites for both CD19 and CD3, leading to T-cell proliferation and activation and B-cell apoptosis. Owing to its short serum half-life, blinatumomab has been administrated by continuous intravenous infusion with a favorable safety profile. The most significant toxicities were central nervous system events and the cytokine release syndrome. This new therapeutic approach using blinatumomab has been shown to be effective in patients with positive minimal residual disease and in patients with R/R B-precursor ALL leading to a recent approval by the US Food and Drug Administration after an accelerated review process. This review focuses on the profile of blinatumomab and its efficacy and safety. Dove Medical Press 2016-02-18 /pmc/articles/PMC4762579/ /pubmed/26937176 http://dx.doi.org/10.2147/DDDT.S83848 Text en © 2016 Le Jeune and Thomas. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Le Jeune, Caroline Thomas, Xavier
spellingShingle	Le Jeune, Caroline Thomas, Xavier Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
author_facet	Le Jeune, Caroline Thomas, Xavier
author_sort	Le Jeune, Caroline
title	Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
title_short	Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
title_full	Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
title_fullStr	Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
title_full_unstemmed	Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
title_sort	potential for bispecific t-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
description	Patients with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) and patients whose minimal residual disease persists during treatment have a poor leukemia-free survival. Despite improvements in front-line therapy, the outcome in these patients remains poor, especially after relapse. As there are no standard chemotherapeutic regimens for the treatment of patients with R/R B-precursor ALL, T-cell-based therapeutic approaches have recently come to the forefront in ALL therapy. Recently, monoclonal antibodies have been developed to target specific antigens expressed in B-lineage blast cells. In this setting, CD19 is of great interest as this antigen is expressed in B-lineage cells. Therefore, it has been selected as the target antigen for blinatumomab, a new bi-specific T-cell engager antibody. This sophisticated antibody binds sites for both CD19 and CD3, leading to T-cell proliferation and activation and B-cell apoptosis. Owing to its short serum half-life, blinatumomab has been administrated by continuous intravenous infusion with a favorable safety profile. The most significant toxicities were central nervous system events and the cytokine release syndrome. This new therapeutic approach using blinatumomab has been shown to be effective in patients with positive minimal residual disease and in patients with R/R B-precursor ALL leading to a recent approval by the US Food and Drug Administration after an accelerated review process. This review focuses on the profile of blinatumomab and its efficacy and safety.
publisher	Dove Medical Press
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762579/
_version_	1613541671234961408

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia

Similar Items